Petros Pharmaceuticals Inc Cash Flow Conversion Efficiency
Petros Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) has a cash flow conversion efficiency ratio of 0.156x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.49 Million) by net assets ($-9.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Petros Pharmaceuticals Inc (2018–2024)
Cash flow conversion efficiency of Petros Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Petros Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Petros Pharmaceuticals Inc (PTPI) share price today for real-time trading data and today's change.
Petros Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Petros Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Petros Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Petros Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Petros Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BOOSH PLANT-BASED BRANDS
F:77I
|
N/A |
|
Chill Brands Group PLC
LSE:CHLL
|
0.919x |
|
Headlam Group
LSE:HEAD
|
-0.182x |
|
Boostheat
PA:ALBOO
|
-8.082x |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
0.025x |
|
Greenroc Mining PLC
LSE:GROC
|
-0.081x |
|
ADVANCED INF SERV(ADVANC)
STU:NVAA
|
0.413x |
|
CAP-XX Limited
LSE:CPX
|
-0.190x |
Annual Cash Flow Conversion Efficiency for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Petros Pharmaceuticals Inc from 2018 to 2024. Review Petros Pharmaceuticals Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.47 Million | $-2.60 Million | 0.349x | +157.04% |
| 2023-12-31 | $12.48 Million | $-7.63 Million | -0.611x | +20.24% |
| 2022-12-31 | $16.70 Million | $-12.80 Million | -0.766x | -129.59% |
| 2021-12-31 | $35.54 Million | $-11.86 Million | -0.334x | +61.91% |
| 2020-12-31 | $17.47 Million | $-15.31 Million | -0.876x | -377.43% |
| 2019-12-31 | $8.02 Million | $2.53 Million | 0.316x | +106.62% |
| 2018-12-31 | $-1.68 Million | $8.02 Million | -4.771x | -- |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.